CN108770974A - 一种抗过敏的益生菌凝胶糖果及其制备方法 - Google Patents
一种抗过敏的益生菌凝胶糖果及其制备方法 Download PDFInfo
- Publication number
- CN108770974A CN108770974A CN201810620253.7A CN201810620253A CN108770974A CN 108770974 A CN108770974 A CN 108770974A CN 201810620253 A CN201810620253 A CN 201810620253A CN 108770974 A CN108770974 A CN 108770974A
- Authority
- CN
- China
- Prior art keywords
- freeze
- dried powder
- powder
- bifidobacterium
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 57
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 57
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 52
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 51
- 230000002804 anti-anaphylactic effect Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 154
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 23
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 22
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 21
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 12
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 12
- 239000008101 lactose Substances 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 9
- 239000000499 gel Substances 0.000 claims description 45
- 241000186000 Bifidobacterium Species 0.000 claims description 20
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 15
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 15
- 244000199866 Lactobacillus casei Species 0.000 claims description 14
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 14
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 14
- 229940017800 lactobacillus casei Drugs 0.000 claims description 13
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 10
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 6
- 241000186012 Bifidobacterium breve Species 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 6
- 229920001202 Inulin Polymers 0.000 claims description 6
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 6
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 6
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 229940029339 inulin Drugs 0.000 claims description 6
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 6
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 6
- 241000186660 Lactobacillus Species 0.000 claims description 5
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 241000186018 Bifidobacterium adolescentis Species 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000000465 moulding Methods 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000000968 intestinal effect Effects 0.000 abstract description 16
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 12
- 208000026935 allergic disease Diseases 0.000 abstract description 9
- 230000007815 allergy Effects 0.000 abstract description 9
- 230000036039 immunity Effects 0.000 abstract description 9
- 244000005700 microbiome Species 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 17
- 230000006870 function Effects 0.000 description 9
- 230000000172 allergic effect Effects 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000345386 Fabia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010181 skin prick test Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/147—Helveticus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/181—Salivarius
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/519—Breve
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/529—Infantis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种抗过敏的益生菌凝胶糖果,其包含以下质量份的原料组分:100份益生菌冻干粉组合物、1‑100份植物干燥粉或提取物、1‑30份功能性低聚糖、1‑10份乳糖、1‑10份水溶性膳食纤维;其中,益生菌冻干粉组合物至少包含罗伊氏乳杆菌冻干粉和长双歧杆菌冻干粉。本发明还公开了一种抗过敏的益生菌凝胶糖果的制备方法。对于本发明,其制备的抗过敏的益生菌凝胶糖果安全无毒副作用,不仅携带方便,能够更便捷、更容易地服用,而且各原料配合科学,通过长期服用,能够改变肠道微生物的组成,调节肠道菌群,提高机体免疫力,从而达到预防和控制过敏的效果。
Description
技术领域
本发明属于食品科学技术领域,具体涉及一种抗过敏的益生菌凝胶糖果及其制备方法。
背景技术
根据卫生假说,过敏的发生除了遗传因素以外,主要是由于婴幼儿时期没有有效接触到一定量的抗原刺激,从而没有形成免疫系统完整功能。现代社会儿童过敏症状发病率普遍提高,主要是由于生活质量提高,很多孩子尤其是生活在城市里的孩子,家长给予的照料以及卫生条件过于洁净,所以没能提供免疫系统完善发育的外界条件,所以对于过敏的预防和控制,显得尤其重要。
通过服用益生菌及具有肠道微生物调节功能的植物提取物组合,可以改善肠免疫系统,同时调节有益菌的平衡,从而提高免疫系统能力,缓解过敏引起的一系列炎症。婴儿肠道双歧杆菌的多样性跟过敏症状密切相关,所以补充多样性的双歧杆菌提高儿童肠道益生菌尤其是双歧杆菌的多样性,对于儿童过敏症状具有很好的帮助。
目前,还没有出现一种抗过敏的益生菌产品,使人们更便捷、更容易地接受,以提高肠道免疫力,从而达到预防和控制过敏的效果。
发明内容
为了克服上述技术缺陷,本发明的第一目的是提供了一种抗过敏的益生菌凝胶糖果,服用方便,通过长期服用,能够改变肠道微生物的组成,调节肠道菌群,提高免疫系统能力,从而达到预防和控制过敏的效果。
为了解决上述问题,本发明按以下技术方案予以实现的:
一种抗过敏的益生菌凝胶糖果,包含以下质量份的原料组分:
100份益生菌冻干粉组合物、1-100份植物干燥粉或提取物、1-30份功能性低聚糖、1-10份乳糖、1-10份水溶性膳食纤维;
所述益生菌冻干粉组合物包含罗伊氏乳杆菌冻干粉、瑞士乳杆菌冻干粉、唾液乳杆菌冻干粉、鼠李糖乳杆菌冻干粉、干酪乳杆菌冻干粉中的至少一种,以及乳双歧杆菌冻干粉、短双歧杆菌冻干粉、两歧双歧杆菌冻干粉、青春双歧杆菌冻干粉、动物双歧杆菌冻干粉、婴儿双歧杆菌冻干粉、长双歧杆菌冻干粉中的至少一种;其中,所述益生菌冻干粉组合物至少包含所述罗伊氏乳杆菌冻干粉和所述长双歧杆菌冻干粉。
罗伊氏乳杆菌、瑞士乳杆菌、唾液乳杆菌、鼠李糖乳杆菌、乳双歧杆菌、干酪乳杆菌、短双歧杆菌、两歧双歧杆菌、青春双歧杆菌、动物双歧杆菌、长双歧杆菌、以及婴儿双歧杆菌是一种常用于酸奶、发酵乳制品及膳食补充剂的益生菌,被列入卫生部公布的《可用于食品的菌种名单》(卫办监督发[2010]65号),可保持肠道的菌群平衡。长双歧杆菌和干酪乳杆菌在发酵过程中可产生胞外多糖,作为一种大分子聚合物,胞外多糖具有一定的粘性和持水性,胞外多糖也是一种有效免疫因子,具有显著调节免疫力的作用。补充多样性的双歧杆菌组合,提高肠道双歧杆菌种类和丰度,对于过敏具有显著调节作用。
进一步的,所述益生菌冻干粉组合物包含所述罗伊氏乳杆菌冻干粉、所述鼠李糖乳杆菌冻干粉、所述干酪乳杆菌冻干粉、所述乳双歧杆菌冻干粉、所述婴儿双歧杆菌冻干粉、所述长双歧杆菌冻干粉;其中,所述罗伊氏乳杆菌冻干粉、所述鼠李糖乳杆菌冻干粉、所述干酪乳杆菌冻干粉、所述乳双歧杆菌冻干粉、所述婴儿双歧杆菌冻干粉、所述长双歧杆菌冻干粉的质量份数比值为:(1-5):(1-5):(1-5):(1-5):(1-5):(1-5)。
罗伊氏乳杆菌是目前已报道的几乎可存在于所有脊椎动物和哺乳动物肠道内的乳酸杆菌,是具有改善过敏体质、预防过敏反复发作,以及调节肠道功能的益生菌。罗伊氏乳杆菌对肠黏膜具有很强的黏附能力,可改善肠道菌落分布,拮抗有害菌定植,避免罹患肠道疾病;罗伊氏乳杆菌能产生一种被称为“罗伊氏菌素”的非蛋白类广谱抗菌物质,能广泛地抑制革兰氏阳性菌、革兰氏阴性菌、酵母、真菌和病原虫等的生长。罗伊氏乳杆菌益生菌制剂可改善人体机能,提高免疫力从而促进人体健康。我国卫生部于2003年批准了罗伊氏乳杆菌可作为人类保健品的微生物菌种,且该菌已是国际上公认的新型益生乳酸菌,具有很高的理论研究和生产应用价值。国内外就罗伊氏乳杆菌对动物健康影响进行研究,Fabia等建立了一个由醋酸诱导大鼠患上溃疡性大肠炎的实验动物模型,他们发现:在进行醋酸饲养后即以5×107-7×107CFU的计量饲喂大鼠肠道特异性罗伊氏乳杆菌,可阻止溃疡性大肠炎的炎症发展。Mao等的试验证明,罗伊氏乳杆菌有助于建立肠道微生态平衡,降低由细菌转移引起的肠道通透性损伤,即有助于削弱由MTX诱导产生的大鼠小肠结肠炎,他们还发现添加罗伊氏乳杆菌会显著增加回肠结肠分泌的IgA水平,同时提高CD4+和CD8+的数量。Indrio等在欧洲医学杂志上发表的最新研究表明,让患有功能性肠道回流症的儿童口服罗伊氏乳杆菌,可减轻其肠道膨胀,加速肠道排空,同时可明显地降低其肠道食物反流的频率。
鼠李糖乳杆菌可改善儿童的急性腹泻与抗生素引起之腹泻,增加白血球的防御能力,所以鼠李糖乳杆菌能吸附肠道黏膜糖蛋白和回肠糖蛋白、定植于肠道内、改善受损肠道黏膜、平衡肠道内菌相、抑制病原菌的生长与抑制E.coli吸附肠道黏膜等多样生理功能。
干酪乳杆菌进入人体后可以在肠道内大量存活,起到调节肠道内菌落平衡、促进人体消化吸收等作用,所以干酪乳杆菌具有促进细胞分裂,产生抗体免疫,增强人体免疫及预防癌症和抑制肿瘤生长等功能,还具有缓解乳糖不耐症、过敏等作用。
乳双歧杆菌具有对胃酸和胆汁的耐受性,通过胃肠道可以存活,并能维持健康的胃肠道菌群。乳双歧杆菌具备瞬时定植在肠道黏膜表面、固定在这些位置的能力,并从而增加了发挥其有益健康功效的可能性。乳双歧杆菌能够维持肠道正常细菌菌群平衡,抑制病原菌的生长。能够抗肿瘤;在肠道内合成维生素、氨基酸和提高机体对钙离子的吸收;降低血液中胆固醇水平,防治高血压;改善乳制品的耐乳糖性,提高消化率;增强人体免疫机能,预防抗生素的副作用,抗衰老;增强机体的非特异性和特异性免疫反应;控制内毒素血症的作用;提高宿主对放射线的耐受性。
婴儿双歧杆菌在母乳喂养儿肠道内大量存在,对婴幼儿有许多好处,如营养、免疫及抗感染作用。并且还具有抗过敏、抗肿瘤、调整肠道功能、改善营养、保护身体不受病原菌的感染、抑制肠内腐败的情况、制造维他命、提高身体的免疫力等作用。
长双歧杆菌是一种重要的肠道有益微生物,其作为一种生理性有益菌,对人体健康具有生物屏障、营养作用、抗肿瘤作用、免疫增强作用、改善胃肠道功能、抗衰老等多种重要的生理功能。在正常情况下,人体内的肠道微生物形成了一个相对平衡的状态。一旦平衡受到破坏,如服用抗生素、放疗、化疗、情绪压抑、身体衰弱、缺乏免疫力等,就会导致肠道菌落失去平衡,某些肠道微生物和产气荚膜等在肠道中过度增殖并产生氨、胺类、硫化氢、粪臭素、吲哚、亚硝酸盐、细菌素等有害物质,影响机体的健康。长双歧杆菌能够抑制人体有害菌的生长,抑制病原菌的感染,合成人体需要的维生素,促进人体对矿物质的吸收,产生醋酸、丙酸、丁酸和乳酸等有机酸刺激肠道蠕动,促进排便,防止便秘以及抑制肠道腐败作用、净化肠道环境、分解致癌物质、刺激人体免疫系统,从而提高抗病能力等方面方面有着重要作用。牛奶含有丰富的营养物质,有些人缺乏乳糖酶,不能分解牛奶中的乳糖,在饮用牛奶后常常出现胃肠道紊乱,导致胃肠痉挛、胀气或腹泻,即为乳糖不耐症,长双歧杆菌能够促进人体对乳糖的消化。
进一步的,所述罗伊氏乳杆菌冻干粉、所述鼠李糖乳杆菌冻干粉、所述干酪乳杆菌冻干粉、所述乳双歧杆菌冻干粉、所述婴儿双歧杆菌冻干粉、所述长双歧杆菌冻干粉的质量份数比值为:2:1:1:2:2:2。
进一步的,包含以下质量份的原料组分:100份益生菌冻干粉组合物、50份植物干燥粉或提取物、15份功能性低聚糖、5份乳糖、6份水溶性膳食纤维。
进一步的,所述植物干燥粉为橙皮粉。
橙皮粉含有橙皮苷,可用作营养强化剂,具有维生素P样效能,具有抗炎、抗病毒等功效。
进一步的,所述功能性低聚糖包含低聚半乳糖、低聚果糖、水苏糖中的至少一种。
功能性低聚糖在人体肠道内没有水解它们的酶系统,因而它们不被消化系统吸收而直接进入大肠内优先为双歧杆菌所利用,是双歧杆菌的增殖因子,具有改善肠道菌落结构等生理作用。
进一步的,所述水溶性膳食纤维包含抗性糊精、菊粉中的至少一种。
抗性糊精由淀粉加工而成,是将焙烤糊精的难消化成分用工业技术提取处理并精炼而成的一种低热量葡聚糖,水溶液黏度很低,并且黏度值随着剪切速率和温度变化而引起的变化微小,抗性糊精具有热量低、耐热、耐酸、耐冷冻等特点。抗性糊精已于2008年年底由“公众营养改善微生态项目”确认为益生元产品,其目标是增加益生元制品在中国的使用,以改善肠道菌落失调。
菊粉是一种天然的水溶性膳食纤维,几乎不能被胃酸水解和消化,只有在结肠被有益微生物利用,从而改善肠道环境。有研究表明,双歧杆菌的增值程度取决于人体大肠中初始双歧杆菌的数量,当初始双歧杆菌数量减少时,使用菊粉后增值效果明显。其次,摄入菊粉后能增强胃肠道蠕动,提高肠胃功能,增加消化和食欲,提高机体免疫力。
为了解决上述问题,本发明的第二目的是提供了一种抗过敏的益生菌凝胶糖果的制备方法,该方法操作简便、易于制造。
为了解决上述问题,本发明按以下技术方案予以实现的:
一种抗过敏的益生菌凝胶糖果的制备方法,包括以下步骤:
S1、配料:100份益生菌冻干粉组合物、1-100份植物干燥粉或提取物、1-30份功能性低聚糖、1-10份乳糖、1-10份水溶性膳食纤维;所述益生菌冻干粉组合物包含罗伊氏乳杆菌冻干粉、瑞士乳杆菌冻干粉、唾液乳杆菌冻干粉、鼠李糖乳杆菌冻干粉、干酪乳杆菌冻干粉中的至少一种,以及乳双歧杆菌冻干粉、短双歧杆菌冻干粉、两歧双歧杆菌冻干粉、青春双歧杆菌冻干粉、动物双歧杆菌冻干粉、婴儿双歧杆菌冻干粉、长双歧杆菌冻干粉中的至少一种;其中,所述益生菌冻干粉组合物至少包含所述罗伊氏乳杆菌冻干粉和所述长双歧杆菌冻干粉;
S2、混料:将步骤S1所得原料在温度小于50℃下搅拌30-60min,得到混合原料;
S3、将步骤S2所得混合原料溶于植物油中,得到混合液;
S4、将步骤S3所得混合液于明胶中凝结成型,得到益生菌凝胶糖果。
进一步的,在步骤S4中,每500mg所述混合液添加260-300mg所述明胶,即得到每粒质量为760-800mg的益生菌凝胶糖果。
进一步的,每粒所述益生菌凝胶糖果含活菌数为5-50×1010CFU。
与现有技术相比,本发明的有益效果是:
(1)本发明提供的一种抗过敏的益生菌凝胶糖果,其包含以下质量份的原料组分:100份益生菌冻干粉组合物、1-100份植物干燥粉或提取物、1-30份功能性低聚糖、1-10份乳糖、1-10份水溶性膳食纤维;其中,益生菌冻干粉组合物至少包含罗伊氏乳杆菌冻干粉和长双歧杆菌冻干粉。该抗过敏的益生菌凝胶糖果安全无毒副作用,不仅携带方便,能够更便捷、更容易地服用,而且各原料配合科学,通过长期服用,能够改变肠道微生物的组成,调节肠道菌群,提高机体免疫力,从而达到预防和控制过敏的效果。
(2)本发明所述的抗过敏的益生菌凝胶糖果,每次服用3-6粒,服用10-60天,可以有效地降低过敏症状。
(3)本发明提供的一种抗过敏的益生菌凝胶糖果的制备方法,操作简便、易于制造,所制备的每粒益生菌凝胶糖果含活菌数为5-50×1010CFU。
附图说明
下面结合附图对本发明的具体实施方式作进一步详细的说明,其中:
图1为本发明所述的抗过敏的益生菌凝胶糖果的制备方法的流程图。
具体实施方式
以下结合附图对本发明的优选实施例进行说明,应当理解,此处所描述的优选实施例仅用于说明和解释本发明,并不用于限定本发明。
本发明公开了一种抗过敏的益生菌凝胶糖果,包含以下质量份的原料组分:100份益生菌冻干粉组合物、1-100份植物干燥粉或提取物、1-30份功能性低聚糖、1-10份乳糖、1-10份水溶性膳食纤维;所述益生菌冻干粉组合物包含罗伊氏乳杆菌冻干粉、瑞士乳杆菌冻干粉、唾液乳杆菌冻干粉、鼠李糖乳杆菌冻干粉、干酪乳杆菌冻干粉中的至少一种,以及乳双歧杆菌冻干粉、短双歧杆菌冻干粉、两歧双歧杆菌冻干粉、青春双歧杆菌冻干粉、动物双歧杆菌冻干粉、婴儿双歧杆菌冻干粉、长双歧杆菌冻干粉中的至少一种;其中,益生菌冻干粉组合物至少包含罗伊氏乳杆菌冻干粉和长双歧杆菌冻干粉。所制得的每粒益生菌凝胶糖果的质量为760-800mg。
各种试验仪器与试剂均为市售商品,均为可通过商业途径购买获得。
实施例1
一种抗过敏的益生菌凝胶糖果,包含以下质量的原料组分:
如图1所示,本实施例还公开了一种抗过敏的益生菌凝胶糖果的制备方法,包括以下步骤:
S1、配料:配备包含以下质量的原料组分:56.82mg罗伊氏乳杆菌冻干粉、28.41mg鼠李糖乳杆菌冻干粉、28.41mg干酪乳杆菌冻干粉、56.82mg乳双歧杆菌冻干粉、56.82mg婴儿双歧杆菌冻干粉、56.82mg长双歧杆菌冻干粉、142.1mg橙皮粉、14.2mg水苏糖、14.2mg低聚半乳糖、14.2mg低聚果糖、14.2mg乳糖、8.5mg抗性糊精、8.5mg菊粉;
S2、混料:将步骤S1所得原料在温度小于50℃下搅拌30min,得到混合原料;温度高于50℃会破坏菌的活性,搅拌时间低于30min会导致搅拌不够均匀;
S3、将步骤S2所得混合原料溶于植物油中,得到混合液;
S4、将步骤S3所得混合液于明胶中凝结成型,得到益生菌凝胶糖果;其中,每500mg混合液添加260-300mg明胶,即得到每粒质量为760-800mg的益生菌凝胶糖果;每粒益生菌凝胶糖果含活菌数为2×1011CFU。
实施例2
一种抗过敏的益生菌凝胶糖果,包含以下质量的原料组分:
其制备过程同实施例1,每粒益生菌凝胶糖果的质量为760-800mg,含活菌数为2×1011CFU。
实施例3
一种抗过敏的益生菌凝胶糖果,包含以下质量的原料组分:
其制备过程同实施例1,每粒益生菌凝胶糖果的质量为760-800mg,含活菌数为2×1011CFU。
实施例4
一种抗过敏的益生菌凝胶糖果,包含以下质量的原料组分:
其制备过程同实施例1,每粒益生菌凝胶糖果的质量为760-800mg,含活菌数为1.5×1011CFU。
实施例5
一种抗过敏的益生菌凝胶糖果,包含以下质量的原料组分:
其制备过程同实施例1,每粒益生菌凝胶糖果的质量为760-800mg,含活菌数为2×1011CFU。
效果试验例
1、感官评价:
表1感官评定结果
项目 | 颜色 | 气味 | 味道 | 质地 |
实施例1 | 淡黄色 | 淡淡的水果清香 | 微甜 | 均匀、无杂质 |
实施例2 | 淡黄色 | 淡淡的水果清香 | 微甜 | 均匀、无杂质 |
实施例3 | 淡黄色 | 淡淡的水果清香 | 微甜 | 均匀、无杂质 |
实施例4 | 淡黄色 | 淡淡的水果清香 | 微甜 | 均匀、无杂质 |
实施例5 | 淡黄色 | 淡淡的水果清香 | 微甜 | 均匀、无杂质 |
注:感官评价为10人小组评定结果。
2、微生物的限量检测:
表2微生物限量检测结果
注:其它理化指标均达到产品质量要求。
3、抗过敏效果的试验:
招募具有对室内灰尘、螨类、花粉、头皮屑等过敏体质的患者120名,男女各60名,排除妊娠与哺乳期的妇女,排除有其它严重疾病者,受试者知情并签署知情同意书。
测试方式:将120名患者随机分成6组,每组20名,分别试用实施例1-5制得的抗过敏的益生菌凝胶糖果辅助治疗,以及1组使用市面上的益生菌产品辅助治疗的对照例。服用方法:每天服用6粒,持续2个月。
测试指标:进行过敏皮肤刺痛试验,肿胀程度:-:没有肿胀(红点直径小于1mm),+:轻微肿胀(红点直径小于2mm),++:肿胀(红点直径小于3mm),+++:肿胀(红点直径为3-5mm),++++:肿胀大(红点直径大于5mm)。收集患者的过敏反应情况,得到的结果如表3所示。
表3患者的过敏反应情况
组别 | 服用前 | 服用10天后 | 服用30天后 | 服用60天后 |
实施例1 | ++++ | ++ | - | - |
实施例2 | ++++ | ++ | + | - |
实施例3 | ++++ | ++ | + | - |
实施例4 | ++++ | +++ | ++ | - |
实施例5 | ++++ | ++ | + | - |
对照例 | ++++ | +++ | +++ | ++ |
由表3可以看出,过敏患者服用实施例1-5的抗过敏的益生菌凝胶糖果后,通过益生菌的辅助治疗,过敏反应情况均得到有效改善,而对照例的改善情况较缓慢,说明实施例1-5制备的抗过敏的益生菌凝胶糖果能有效控制患者的过敏情况。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,故凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何修改、等同变化与修饰,均仍属于本发明技术方案的范围内。
Claims (10)
1.一种抗过敏的益生菌凝胶糖果,其特征在于,包含以下质量份的原料组分:
100份益生菌冻干粉组合物、1-100份植物干燥粉或提取物、1-30份功能性低聚糖、1-10份乳糖、1-10份水溶性膳食纤维;
所述益生菌冻干粉组合物包含罗伊氏乳杆菌冻干粉、瑞士乳杆菌冻干粉、唾液乳杆菌冻干粉、鼠李糖乳杆菌冻干粉、干酪乳杆菌冻干粉中的至少一种,以及乳双歧杆菌冻干粉、短双歧杆菌冻干粉、两歧双歧杆菌冻干粉、青春双歧杆菌冻干粉、动物双歧杆菌冻干粉、婴儿双歧杆菌冻干粉、长双歧杆菌冻干粉中的至少一种;其中,所述益生菌冻干粉组合物至少包含所述罗伊氏乳杆菌冻干粉和所述长双歧杆菌冻干粉。
2.根据权利要求1所述的抗过敏的益生菌凝胶糖果,其特征在于:所述益生菌冻干粉组合物包含所述罗伊氏乳杆菌冻干粉、所述鼠李糖乳杆菌冻干粉、所述干酪乳杆菌冻干粉、所述乳双歧杆菌冻干粉、所述婴儿双歧杆菌冻干粉、所述长双歧杆菌冻干粉;其中,所述罗伊氏乳杆菌冻干粉、所述鼠李糖乳杆菌冻干粉、所述干酪乳杆菌冻干粉、所述乳双歧杆菌冻干粉、所述婴儿双歧杆菌冻干粉、所述长双歧杆菌冻干粉的质量份数比值为:(1-5):(1-5):(1-5):(1-5):(1-5):(1-5)。
3.根据权利要求2所述的抗过敏的益生菌凝胶糖果,其特征在于:所述罗伊氏乳杆菌冻干粉、所述鼠李糖乳杆菌冻干粉、所述干酪乳杆菌冻干粉、所述乳双歧杆菌冻干粉、所述婴儿双歧杆菌冻干粉、所述长双歧杆菌冻干粉的质量份数比值为:2:1:1:2:2:2。
4.根据权利要求1所述的抗过敏的益生菌凝胶糖果,其特征在于,包含以下质量份的原料组分:
100份益生菌冻干粉组合物、50份植物干燥粉或提取物、15份功能性低聚糖、5份乳糖、6份水溶性膳食纤维。
5.根据权利要求1所述的抗过敏的益生菌凝胶糖果,其特征在于:所述植物干燥粉包含橙皮粉。
6.根据权利要求1所述的抗过敏的益生菌凝胶糖果,其特征在于:所述功能性低聚糖包含低聚半乳糖、低聚果糖、水苏糖中的至少一种。
7.根据权利要求1所述的抗过敏的益生菌凝胶糖果,其特征在于:所述水溶性膳食纤维包含抗性糊精、菊粉中的至少一种。
8.一种根据权利要求1~7任一项所述的抗过敏的益生菌凝胶糖果的制备方法,其特征在于,包括以下步骤:
S1、配料:100份益生菌冻干粉组合物、1-100份植物干燥粉或提取物、1-30份功能性低聚糖、1-10份乳糖、1-10份水溶性膳食纤维;所述益生菌冻干粉组合物包含罗伊氏乳杆菌冻干粉、瑞士乳杆菌冻干粉、唾液乳杆菌冻干粉、鼠李糖乳杆菌冻干粉、干酪乳杆菌冻干粉中的至少一种,以及乳双歧杆菌冻干粉、短双歧杆菌冻干粉、两歧双歧杆菌冻干粉、青春双歧杆菌冻干粉、动物双歧杆菌冻干粉、婴儿双歧杆菌冻干粉、长双歧杆菌冻干粉中的至少一种;其中,所述益生菌冻干粉组合物至少包含所述罗伊氏乳杆菌冻干粉和所述长双歧杆菌冻干粉;
S2、混料:将步骤S1所得原料在温度小于50℃下搅拌30-60min,得到混合原料;
S3、将步骤S2所得混合原料溶于植物油中,得到混合液;
S4、将步骤S3所得混合液于明胶中凝结成型,得到益生菌凝胶糖果。
9.根据权利要求8所述的抗过敏的益生菌凝胶糖果的制备方法,其特征在于:在步骤S4中,每500mg所述混合液添加260-300mg所述明胶,即得到每粒质量为760-800mg的益生菌凝胶糖果。
10.根据权利要求9所述的抗过敏的益生菌凝胶糖果的制备方法,其特征在于:每粒所述益生菌凝胶糖果含活菌数为5-50×1010CFU。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810620253.7A CN108770974A (zh) | 2018-06-15 | 2018-06-15 | 一种抗过敏的益生菌凝胶糖果及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810620253.7A CN108770974A (zh) | 2018-06-15 | 2018-06-15 | 一种抗过敏的益生菌凝胶糖果及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108770974A true CN108770974A (zh) | 2018-11-09 |
Family
ID=64026191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810620253.7A Pending CN108770974A (zh) | 2018-06-15 | 2018-06-15 | 一种抗过敏的益生菌凝胶糖果及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108770974A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109480231A (zh) * | 2018-11-16 | 2019-03-19 | 广州普维君健药业有限公司 | 抗幽门螺杆菌的组合物及其应用 |
CN110771682A (zh) * | 2019-11-27 | 2020-02-11 | 江西中医药大学 | 一种抗过敏酸奶及其制备方法 |
CN111264665A (zh) * | 2020-03-20 | 2020-06-12 | 佛山科学技术学院 | 一种蜜柚风味益生菌动物凝胶糖果及其制备方法 |
CN111587945A (zh) * | 2020-05-27 | 2020-08-28 | 广州富诺营养科技有限公司 | 一种含有唾液酸的凝胶糖果及其制备方法与应用 |
CN112088967A (zh) * | 2020-09-24 | 2020-12-18 | 湖南素囊健康科技有限公司 | 一种适合婴幼儿的益生菌凝胶糖果及其制备方法 |
CN113908176A (zh) * | 2021-11-30 | 2022-01-11 | 浙江工商大学 | 一种防治食物过敏的组合物 |
CN117887643A (zh) * | 2024-03-14 | 2024-04-16 | 微康益生菌(苏州)股份有限公司 | 一种抗过敏的益生菌剂及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165557A1 (en) * | 2000-09-19 | 2003-09-04 | Sunstar, Inc. | Food, medicine and method relating to Bifidobacterium proliferation promoting action, allergy preventive action and human cholesterol lowering action |
CN107669706A (zh) * | 2017-11-18 | 2018-02-09 | 宁波绿康康复科技有限公司 | 用于治疗和预防过敏性疾病的复合益生菌及其制备方法以及型剂 |
CN107897475A (zh) * | 2017-11-22 | 2018-04-13 | 东莞亿智食品有限公司 | 一种益生菌低聚糖果及其制作方法 |
CN107912589A (zh) * | 2017-12-21 | 2018-04-17 | 广州莱可福生物科技有限公司 | 含益生菌且可改善肠道和免疫力的压片糖果及其制备方法 |
-
2018
- 2018-06-15 CN CN201810620253.7A patent/CN108770974A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030165557A1 (en) * | 2000-09-19 | 2003-09-04 | Sunstar, Inc. | Food, medicine and method relating to Bifidobacterium proliferation promoting action, allergy preventive action and human cholesterol lowering action |
CN107669706A (zh) * | 2017-11-18 | 2018-02-09 | 宁波绿康康复科技有限公司 | 用于治疗和预防过敏性疾病的复合益生菌及其制备方法以及型剂 |
CN107897475A (zh) * | 2017-11-22 | 2018-04-13 | 东莞亿智食品有限公司 | 一种益生菌低聚糖果及其制作方法 |
CN107912589A (zh) * | 2017-12-21 | 2018-04-17 | 广州莱可福生物科技有限公司 | 含益生菌且可改善肠道和免疫力的压片糖果及其制备方法 |
Non-Patent Citations (1)
Title |
---|
《生命时报》编辑部主编: "《生命妙方 养生防病偏方 验方大全 上》", 31 May 2016, 贵州科技出版社 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109480231A (zh) * | 2018-11-16 | 2019-03-19 | 广州普维君健药业有限公司 | 抗幽门螺杆菌的组合物及其应用 |
CN110771682A (zh) * | 2019-11-27 | 2020-02-11 | 江西中医药大学 | 一种抗过敏酸奶及其制备方法 |
CN111264665A (zh) * | 2020-03-20 | 2020-06-12 | 佛山科学技术学院 | 一种蜜柚风味益生菌动物凝胶糖果及其制备方法 |
CN111587945A (zh) * | 2020-05-27 | 2020-08-28 | 广州富诺营养科技有限公司 | 一种含有唾液酸的凝胶糖果及其制备方法与应用 |
CN112088967A (zh) * | 2020-09-24 | 2020-12-18 | 湖南素囊健康科技有限公司 | 一种适合婴幼儿的益生菌凝胶糖果及其制备方法 |
CN113908176A (zh) * | 2021-11-30 | 2022-01-11 | 浙江工商大学 | 一种防治食物过敏的组合物 |
CN113908176B (zh) * | 2021-11-30 | 2024-02-09 | 浙江工商大学 | 一种防治食物过敏的组合物 |
CN117887643A (zh) * | 2024-03-14 | 2024-04-16 | 微康益生菌(苏州)股份有限公司 | 一种抗过敏的益生菌剂及其应用 |
CN117887643B (zh) * | 2024-03-14 | 2024-06-14 | 微康益生菌(苏州)股份有限公司 | 一种抗过敏的益生菌剂及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108770974A (zh) | 一种抗过敏的益生菌凝胶糖果及其制备方法 | |
CN100489086C (zh) | 能够刺激粘膜免疫性的乳酸菌 | |
EP1137424B9 (en) | Preparation which contains oligosaccharides and probiotics | |
CN108740251A (zh) | 一种改善便秘的益生菌凝胶糖果及其制备方法 | |
CN108991327A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN104642870B (zh) | 一种益生元组合物 | |
CN109123295A (zh) | 一种益生菌固体饮料及其制备方法 | |
CN108004189A (zh) | 一种复合益生乳酸菌粉剂及其制备方法与应用 | |
CN108823129B (zh) | 一种具有抵抗幽门螺旋杆菌作用的高活性益生菌固体饮料 | |
CN108850397A (zh) | 一种止腹泻的益生菌凝胶糖果及其制备方法 | |
Ishibashi et al. | Bifidobacteria: their significance in human intestinal health | |
CN107691955A (zh) | 益生菌固体饮料及其制备方法 | |
CN107115364A (zh) | 一种复合益生菌及其制备方法 | |
WO2007140622A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
WO2007140621A1 (en) | Probiotic compositions and uses thereof | |
CN108041169A (zh) | 一种含益生菌和益生元的儿童用固体饮料及其制备方法 | |
CN110353144A (zh) | 一种益生菌固体饮料及其制备工艺 | |
KR20010101531A (ko) | 개선된 미생물 제제 | |
CN107095292A (zh) | 一种具有调节肠道菌群功能的植物复合酵素及其制备方法 | |
CN112056399A (zh) | 一种增强免疫力的益生菌组合物及其应用 | |
CN110521939A (zh) | 一种调节肠道健康的益生菌发酵食品及其制备方法 | |
CN108208843A (zh) | 一种调节肠道菌群的保健组合物及其用途 | |
CN109315769A (zh) | 一种用于改善人体肠内环境的组合物及其制备方法 | |
CN105982009A (zh) | 用于调节人体肠道微生态的组合物 | |
Lokhande et al. | A systematic study of probiotics-an update review |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181109 |